nevirapine

nevirapine
Name	Nevirapine
Tradenames	Viramune, others
Legal status	Rx-only
Routes of administration	Oral
Class	Non-nucleoside reverse transcriptase inhibitor
Bioavailability	High
Protein binding	~60%
Metabolism	Hepatic (CYP3A4, CYP2B6)
Elimination half-life	25–30 hours (single dose), 45 hours (chronic)
Excretion	Feces

nevirapine

Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment and prevention of human immunodeficiency virus type 1 infection. It is prescribed as part of combination antiretroviral therapy and has been employed in peripartum prophylaxis to reduce mother-to-child transmission. Originating from pharmaceutical development in the late 20th century, the drug has played a role in global HIV programs and public health initiatives.

Medical uses

Nevirapine is indicated for the management of HIV/AIDS as part of combination regimens alongside agents such as zidovudine, lamivudine, tenofovir, efavirenz, and lopinavir/ritonavir. It has been used in resource-limited settings supported by programs involving World Health Organization and United Nations agencies for prevention of vertical transmission during labor, often in single-dose strategies integrated with antiretroviral therapy rollouts led by organizations like Médecins Sans Frontières and Centers for Disease Control and Prevention. Clinical guidelines from bodies such as the British HIV Association and the Department of Health and Human Services have historically included nevirapine in first-line or alternative regimens, particularly where access to other drugs was limited. Trials coordinated by groups like the HIV Prevention Trials Network and investigators associated with institutions such as Johns Hopkins University and University of Cape Town informed dosing and population-specific recommendations.

Mechanism of action

Nevirapine binds directly to the reverse transcriptase enzyme of HIV-1, inducing conformational changes that inhibit RNA-dependent and DNA-dependent DNA polymerase activities. Structural studies from laboratories at institutions including National Institutes of Health, Scripps Research Institute, and University of Oxford revealed the non-competitive binding at a distinct hydrophobic pocket near the active site, differing from nucleoside analogues developed by teams at GlaxoSmithKline and other pharmaceutical companies. Biochemical assays from research groups affiliated with Rockefeller University and Massachusetts Institute of Technology demonstrated suppression of viral replication in cell lines and primary lymphocytes, which translated into reduced plasma viral load in clinical trials run by cooperative groups such as the International AIDS Society-affiliated networks.

Pharmacology

Nevirapine is orally bioavailable and undergoes extensive hepatic metabolism primarily via cytochrome P450 isoenzymes supported by studies at Mayo Clinic and Cleveland Clinic. Its pharmacokinetic profile includes a relatively long half-life after multiple dosing, leading to steady-state concentrations characterized in pharmacology studies from University College London and Harvard Medical School. Population pharmacokinetic analyses incorporating cohorts from Kenya, South Africa, and Brazil—often in collaboration with UNAIDS—identified variability related to genetic polymorphisms in enzymes such as CYP2B6, noted by pharmacogenetics groups at University of Cape Town and University of Ghana. Formulation work by manufacturers and regulatory science groups at Food and Drug Administration-associated labs addressed stability and dosing in fixed-dose combinations used in public health programs run by UNICEF and national health ministries.

Adverse effects and toxicity

Hepatotoxicity and severe cutaneous reactions, including Stevens–Johnson syndrome, have been the principal serious adverse effects prompting boxed warnings by regulators including the Food and Drug Administration and European Medicines Agency. Post-marketing surveillance coordinated with institutions such as World Health Organization pharmacovigilance programs reported cases of fulminant hepatic failure managed in tertiary centers like Royal Free Hospital and Groote Schuur Hospital. Common adverse events documented in randomized trials conducted by networks including ACTG and INSIGHT include rash, fever, and gastrointestinal symptoms; dermatologic cases sometimes necessitated discontinuation per protocols developed at King's College Hospital and St. Mary's Hospital. Hepatic monitoring recommendations originated from collaborative guideline panels including representatives from American Academy of HIV Medicine and national infectious disease societies.

Interactions and contraindications

Because nevirapine induces cytochrome P450 enzymes, particularly CYP3A4 and CYP2B6, it interacts with numerous drugs reviewed by experts at European AIDS Clinical Society and British Pharmacological Society. Clinically significant interactions have been reported with agents such as warfarin, oral contraceptives, certain statins, and antimycobacterial drugs used for tuberculosis treatment like rifampicin—findings from drug interaction studies conducted at UCLA and University of Stellenbosch. Contraindications include pre-existing severe hepatic impairment and prior hypersensitivity; risk mitigation strategies developed by panels at WHO and national regulatory agencies advise caution in pregnancy and when co-administering hepatotoxic drugs, with management pathways utilized in referral centers like Mbarara Hospital and Addenbrooke's Hospital.

History and regulatory status

Nevirapine was discovered in medicinal chemistry programs of the late 1980s and brought to approval following clinical development involving corporate and academic collaborations, with regulatory approvals granted by agencies such as the Food and Drug Administration and European Medicines Agency in the 1990s. Its role in global HIV programs expanded through licensing agreements, generic manufacturing by companies in India and supply initiatives by Global Fund and PEPFAR. Controversies over single-dose use for vertical transmission and patent disputes engaged organizations such as Doctors Without Borders and legal forums in South Africa and United States District Court for the Southern District of New York, shaping access and pricing policies. Ongoing inclusion in national formularies and treatment guidelines, influenced by evidence syntheses from groups like the Cochrane Collaboration and policy work at UNAIDS, reflects its continued, though more limited, role amid newer antiretroviral classes championed at conferences organized by International AIDS Conference and academic centers globally.

Category:Antiretroviral drugs